Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study
Blood
.
2018 Aug 2;132(5):547-550.
doi: 10.1182/blood-2018-03-835413.
Epub 2018 Jun 13.
Authors
Giuseppe Rossi
1
,
Doriana Gramegna
1
,
Francesca Paoloni
2
,
Bruno Fattizzo
3
,
Francesca Binda
3
,
Mariella D'Adda
1
,
Mirko Farina
1
,
Elisa Lucchini
4
,
Francesca Romana Mauro
5
,
Flavia Salvi
6
,
Monia Marchetti
7
,
Paola Fazi
2
,
Francesco Zaja
4
,
Wilma Barcellini
3
Affiliations
1
Department of Hematology, ASST Spedali Civili, Brescia, Italy.
2
Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Onlus Foundation, Rome, Italy.
3
Hematology Unit-IRCCS Ca' Granda Hospital, Milan, Italy.
4
Department of Hematology DISM-University of Udine, Udine, Italy.
5
Department of Cellular Biotechnology and Hematology-"Sapienza" University, Rome, Italy.
6
Hematology-SS Antonio Hospital, Biagio e C. Arrigo, Alessandria, Italy; and.
7
Hematology Unit, Cardinal Massaia Hospital, Asti, Italy.
PMID:
29898955
DOI:
10.1182/blood-2018-03-835413
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Anemia, Hemolytic, Autoimmune*
Bortezomib
Humans
Metadata
Neoplasm Recurrence, Local
Prospective Studies
Translational Research, Biomedical
Workflow
Substances
Bortezomib